Names
Glofitamab-gxbm Columvi™Indications and usage
Glofitamab-gxbm is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.
Side effects needing medical attention
The most common adverse reactions are cytokine release syndrome (CRS), musculoskeletal pain, rash, and fatigue.
The most common Grade 3 to 4 laboratory abnormalities are lymphocyte count decreased, phosphate decreased, neutrophil count decreased, uric acid increased, and fibrinogen decreased.